AGENTS DE LIAISON OCTAMÈRES TÉTRASPÉCIFIQUES ET ANTICORPS ANTI-TOXINE A ET ANTI-TOXINE B DE CLOSTRIDIUM DIFFICILE POUR LE TRAITEMENT DE L'INFECTION À C. DIFFICILE
Novel, antibody-based binding agents derived from human and camelid immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.